Sugi Predict

Sugi Predict / Compounds / SCHEMBL1406763

SCHEMBL1406763

SCHEMBL1406763

CC1(C)CCC(C)(C)c2c(C3=CCN(CCC(=O)O)CC3)cc(C(O)C#Cc3ccc(C(=O)O)cc3)cc21

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ RARB P10826 12/20 0.39
▸ RARG P13631 12/20 0.39
▸ RARA P10276 10/20 0.39
▸ CYP26A1 O43174 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ CRABP2 P29373 1/20 0.39
▸ CYP26B1 Q9NR63 1/20 0.36
▸ RXRA P19793 2/20 0.36
▸ S1PR1 P21453 1/20 0.36
▸ S1PR3 Q99500 1/20 0.36
▸ RXRB P28702 1/20 0.34
▸ SUV39H2 Q9H5I1 1/20 0.34
▸ SIGMAR1 Q99720 1/20 0.34
▸ S1PR5 Q9H228 1/20 0.33
▸ HNF4A P41235 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407054 0.89 S1PR1 (0.34) S1PR1S1PR3SUV39H2SIGMAR1S1PR5
SCHEMBL1406490 0.89 RARB (0.42) RARBRARGRARACYP26A1CYP3A4
SCHEMBL1406623 0.85 RARB (0.43) RARBRARGRARACYP26A1CYP3A4
SCHEMBL1406762 0.84 RARB (0.40) RARBRARGRARACYP26A1CYP3A4
SCHEMBL1406876 0.81 RARB (0.42) RARBRARGRARACYP26A1CYP3A4
SCHEMBL1406776 0.78 HDAC8 (0.33) RARBRARGRARACYP26A1CYP3A4
SCHEMBL6424615 0.78 RARA (0.37) RARBRARGRARACYP26A1CYP3A4
SCHEMBL6424618 0.78 RARA (0.37) RARBRARGRARACYP26A1CYP3A4
SCHEMBL1406616 0.77 RARG (0.50) RARBRARGRARACYP26A1CYP3A4
SCHEMBL1406704 0.77 RARB (0.40) RARBRARGRARACYP26A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 — — EP claimed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 — — US claimed
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 — — EP disclosed
US-7468457-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-23 — — US disclosed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARB 2/4885RARG 3/4885RARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.